What We Do

At the ceedd we seek to preserve our alliance companies' independence and creativity. Our team works with you from initial discussions on forming a collaboration, providing advice and expertise through the years of program development after a deal has been signed and finally championing the transition of the asset into GSK at clinical proof of concept.

A ceedd alliance can include programs starting at any point in development from target to clinical proof of concept (PoC). Ideally these programs will be generated from an innovative platform technology and GSK will have an exclusive right to option these programs at clinical PoC.

This is a very different approach to classical in-licensing which tends to focus on single products, which are often much later in development, and brought immediately into GSK for further development.

The ceedd model has been adopted by the other R&D Therapeutic Area Units (TAU), but they remain focused on single therapy areas, and also have their own pipeline to prosecute.

The ceedd remains unique, working across multiple therapy areas, with no internal programs to manage. We are purely focused on your success. We have a wealth of expertise and experience working with innovative biotech companies, resulting in nine ongoing collaborations, and in five years have successfully transitioned three assets at clinical proof of concept into GSK for further development.